Literature DB >> 22811258

Prognostic value of quantitative parameters derived on initial staging 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with high-grade non-Hodgkin's lymphoma.

Kuruva Manohar1, Bhagwant R Mittal, Anish Bhattacharya, Pankaj Malhotra, Subhash Varma.   

Abstract

OBJECTIVES: This study was carried out to evaluate the role of quantitative parameters in staging PET in predicting prognosis in patients with high-grade non-Hodgkin's lymphoma (NHL).
METHODS: A total of 51 histopathologically proven high-grade NHL patients treated with conventional chemotherapy regimens were included in the study. Total lesion glycolysis (TLG) and functional volumes (FVs) were defined as per the PET Response Criteria in Solid Tumors (PERCIST) criteria. All patients were followed up for a minimum period of 1 year or until an event, whichever occurred earlier.
RESULTS: Of the four semiquantitative parameters studied, SUV max and SUV mean did not show a statistically significant correlation with progression-free survival or overall survival, whereas TLG and FV showed a weak but statistically significant negative correlation. Using the receiver operating characteristic curve analysis, optimal cut-offs were derived for FV and TLG to predict progression and death. Using the cut-off values of 416 cm3 and 3340 g for FV and TLG, respectively, a statistically significant difference in progression-free survival and overall survival was obtained in the groups with FV and TLG above and below the threshold. On multivariate analysis of all the conventional prognostic factors and TLG more than 3340 and FV more than 416 cm3, only age greater than 60 years (P=0.013) and FV more than 416 cm3 (P=0.012) were found to be independently associated with disease progression.
CONCLUSION: Our results indicate that FV and TLG in staging PET/CT could be useful indices in predicting outcomes in patients with high-grade NHL treated with standard first-line chemotherapy regimens.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22811258     DOI: 10.1097/MNM.0b013e32835673ec

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  12 in total

1.  Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume.

Authors:  Luca Ceriani; Lisa Milan; Peter W M Johnson; Maurizio Martelli; Stefano Presilla; Luca Giovanella; Emanuele Zucca
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-02-26       Impact factor: 9.236

2.  A 60-year-old Indian male with altered sensorium and extensive lymphoma of the scalp.

Authors:  Budhi S Yadav; Anshuma Bansal; Suresh C Sharma; Pankaj Malhotra; Nilanjan Ghosh; Matthias Holdhoff; Andrei Shustov; Marc Chamberlain; Herbert Newton; Priya Kumethkar; Jeffrey N Raizer; Jon Glass; Gloria J Morris
Journal:  Semin Oncol       Date:  2013-06       Impact factor: 4.929

3.  Quantitative analysis of image metrics for reduced and standard dose pediatric 18F-FDG PET/MRI examinations.

Authors:  Pietro Zucchetta; Marco Branchini; Alessandra Zorz; Valentina Bodanza; Diego Cecchin; Marta Paiusco; Franco Bui
Journal:  Br J Radiol       Date:  2019-01-23       Impact factor: 3.039

4.  Baseline total lesion glycolysis measured with (18)F-FDG PET/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study.

Authors:  Shadi A Esfahani; Pedram Heidari; Elkan F Halpern; Ephraim P Hochberg; Edwin L Palmer; Umar Mahmood
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-04-09

Review 5.  Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0.

Authors:  Joo Hyun O; Martin A Lodge; Richard L Wahl
Journal:  Radiology       Date:  2016-02-24       Impact factor: 11.105

6.  Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

Authors:  Sally F Barrington; N George Mikhaeel; Lale Kostakoglu; Michel Meignan; Martin Hutchings; Stefan P Müeller; Lawrence H Schwartz; Emanuele Zucca; Richard I Fisher; Judith Trotman; Otto S Hoekstra; Rodney J Hicks; Michael J O'Doherty; Roland Hustinx; Alberto Biggi; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

7.  FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma.

Authors:  Vasavi Paidpally; Alin Chirindel; Stella Lam; Nishant Agrawal; Harry Quon; Rathan M Subramaniam
Journal:  Imaging Med       Date:  2012-12

8.  Value of CT, FDG PET-CT and serum tumor markers in staging recurrent colorectal cancer.

Authors:  Meltem Caglar; Can Yener; Erdem Karabulut
Journal:  Int J Comput Assist Radiol Surg       Date:  2014-09-12       Impact factor: 2.924

Review 9.  Tumor quantification in clinical positron emission tomography.

Authors:  Bing Bai; James Bading; Peter S Conti
Journal:  Theranostics       Date:  2013-10-07       Impact factor: 11.556

Review 10.  Review of clinical practice utility of positron emission tomography with 18F-fluorodeoxyglucose in assessing tumour response to therapy.

Authors:  Andrea d'Amico
Journal:  Radiol Med       Date:  2014-08-26       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.